Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13307458 | 0.93 | ATM (0.56) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL12852909 | 0.93 | ATM (0.60) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL7247261 | 0.88 | HTT (0.54) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL3580457 | 0.85 | KMT2A (0.51) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL3759687 | 0.85 | KMT2A (0.51) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL29957193 | 0.85 | KMT2A (0.51) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL17615093 | 0.85 | KMT2A (0.51) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL3166508 | 0.84 | GPBAR1 (0.53) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL28967010 | 0.84 | ATM (0.51) | ATMKMT2AHTTMEN1HPGD | |
| SCHEMBL20474525 | 0.82 | ATM (0.57) | ATMKMT2AHTTMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417120-B1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| WO-2010115836-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | WEIGAND KLAUS | 2008-12-11 | — | — | US | disclosed |
| EP-1943235-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Novartis AG (CH) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007048771-A1 | ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306067-A1 | Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR4 | ATM 3530/4885KMT2A 4826/4885HTT 4831/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | ATM 4130/4885KMT2A 3453/4885HTT 3830/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | ATM 4190/4885KMT2A 3391/4885HTT 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.